Dr. Jason Mellad (CEO) is the Chief Executive Officer at Cambridge Epigenetix. Before joining the company, he served as Business Development Manager at Horizon Discovery and also has extensive experience in the fields of technology transfer, IP management and product innovation consultancy. Jason has a BSc in Molecular Biology and Chemistry from Tulane University and was a Marshall Scholar at the University of Cambridge where he completed a PhD in Medicine.
Deborah Tonge, ACMA (Head of Finance & Operations) spent her early career in the City, training initially with the International Stock Exchange then moving to Lloyds Bank. Following a move to Salomon Smith Barney investment Bank she became Management Accountant for the Business Technology Division and then headed a department responsible for Financial Management for Europe and the Financial Division in London. Before joining CEGX Deborah worked for Cambridge Cognition for 5 years while also maintaining a small private practice for small start-up companies in Cambridge and London.
Dr. Michael Steward (Head of Research) has held numerous scientific leadership roles within the biotech and pharmaceutical sectors with a focus on biopharmaceutical R&D, most recently as head of Antibody Technologies at GSK. During his career, Michael has developed therapeutic and diagnostic antibodies and other molecular tests for a range of diseases and created novel workflows and processes to expedite discovery processes. He is a named author on >30 scientific publications and many patents. Michael’s role at CEGX is to bring forward novel products for detection of epigenetic marks and to make these as accessible as possible to the research and drug discovery community.
Dr. Stephanie Brooking (VP Marketing and Sales) has spent almost 19 years working with cutting edge innovative technologies in commercial roles. Most recently, Steph was Director of Commercial at Oxford Nanopore Technologies, where she served for nearly 5 years building out the commercial function and team. Prior to ONT, Steph gained extensive experience in the fields of NGS and arrays working for Illumina as a European Sequencing specialist and in business development at Applied Biosystems, complemented by roles with Affymetrix and Amersham Pharmacia Biosciences.
Dr. Olga Gandelman MBA, (Head of Assay Development) leads assay development activities at CEGX. Her experience in MDx assay and technology development was gained in successful start-ups and SMEs over 15 years. Prior to CEGX Olga was a Senior Assay Development Manager at Epistem heading a team of world-class scientists working on point-of-care medical, environmental and industrial applications. As a leading scientist at Lumora Ltd, spun-out from Cambridge University that she joined from start-up, Olga was the inventor of Lumora’s proprietary BART technology and several core patents that later led to the acquisition by Roche and ERBA Mannheim. Olga has a first degree and PhD from MSU, Russia, and held postdoctoral research positions with MSU, University of Liverpool, UK (Wellcome Trust Fellowship) and Cambridge University, UK (Daphne Jackson Trust Fellowship).
Dr. Tobias Ost (VP Advanced Research) leads day-to-day R&D activities at CEGX. Toby has broad and deep experience of next generation sequencing. He was one of the key R&D Scientists responsible for developing the Solexa SBS sequencing chemistry, including co-invention of the paired-end methodology and second generation sequencing enzyme. Subsequently he was a Field Application Scientist firstly with Illumina and then with Pacific Biosciences, where he became European Field Application Specialists Manager. These roles required him to support leading edge sequencing customers and manage early-stage product introduction.